International Theft of Trade Secrets, International Patent Infringement, and International Intellectual Property Rights Infringement are on the Rise by International Patent Infringement Government Procurement Whistleblower Reward Lawyer, International Trade Secret Theft Procurement Whistleblower Lawyer, and International Patent Infringement Supply Chain Import Business Litigation Lawyer Jason S. Coomer

International Theft of Trade Secrets, International Patent Infringement, and International Intellectual Property Rights Infringement are on the Rise by International Patent Infringement Government Procurement Whistleblower Reward Lawyer, International Trade Secret Theft Procurement Whistleblower Lawyer, and International Patent Infringement Supply Chain Import Business Litigation Lawyer Jason S. Coomer

International theft of trade secrets and international intellectual property right infringement are on the rise as China, Mexico, Russia, and other emerging countries are seeking to improve their technology to move up the manufacturing value chain.  With fierce competition from countries such as Vietnam, Cambodia and Bangladesh attempting to undercut China's manufacturing of labor-intensive goods as well as higher end supply chain manufacturing competition from other emerging countries being placed on China, Russia, and Mexico; the pressure to obtain high end trade secrets and intellectual property has led to corporate espionage and theft of valuable trade secrets and intellectual property.  These products when used in other products can come through the supply chain and be the basis for patent infringement lawsuits, whistleblower reward lawsuits, and other types of lawsuits.

International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, and International Business Litigation Lawsuits

International theft of trade secret lawsuits, international patent infringement lawsuits, international intellectual property right infringement lawsuits, and other international business litigation lawsuits can be complicated legal matters requiring an experienced legal team to work across jurisdictions and work with different government entities.   These cases can become procurement fraud whistleblower reward lawsuits when internationally produced products reenter the United States and are sold to the U.S. Government or another governmental entity.

---

Establish U.S. Government-Wide Working Group to Prevent U.S. Government Purchase of Counterfeit Products
The 2011 IPEC Annual Report on Intellectual Property Enforcement

As the purchaser of over $500 billion in goods and services per year, the U S Government must ensure that it does not purchase counterfeit goods, secure its supply chain, and take the necessary steps to combat the evolving tactics of counterfeiters The Joint Strategic Plan established a government-wide working group to prevent the purchase and use of counterfeit products Over the last year, the IPEC convened an interagency group consisting of subject matter experts to develop an anti-counterfeiting framework that is flexible enough to accommodate the wide variety of missions across the government and their different systems of procurement The Office of Federal Procurement Policy (OFPP), Department of Defense (DOD), DOJ, and NASA have assumed leadership roles within the working group based on their vast expertise with U S Government procurement and anti-counterfeiting practices Other members include the DOC, Department of Energy, HHS, DHS, and Department of Transportation, the Environmental Protection Agency, the Missile Defense Agency, the General Services Administration, the Small Business Administration, the Nuclear Regulatory Commission, and the National Reconnaissance Office The main focus of this interagency working group is to ensure that the U S Government has the necessary tools to ensure that it does not purchase or use counterfeit products The working group is examining legislative authority, regulations, procurement policy and guidance, industry studies and reports, and international anti-counterfeiting standards in order to identify areas where risk to the security of U S Government supply chain from counterfeit parts can be reduced The working group developed six objectives to focus the group’s efforts to identify legislative, regulatory, or policy gaps and propose solutions to fill those gaps The six objectives are:

• Counterfeit Risk Assessment
• Supplier Requirements
• Traceability
• Testing and Evaluation of Goods
• Counterfeit Training and Outreach
• Enforcement Remedies

The group is developing a government-wide strategy using tools that are already at the U S Government’s disposal and creating new tools to combat the purchase or use of counterfeit goods by the U S Government The strategy will focus on reducing the risk of counterfeit items entering the supply chain, dealing efficiently with any suspected counterfeit items that do enter the supply chain, and strengthening remedies against those who provide counterfeit items to the U S Government.

International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, and International Business Litigation Lawsuits

For more information on International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, please click on the following link: International Patent Infringement Government Procurement Reward Lawsuit, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuit, International Supply Chain Procurement Fraud Whistleblower Lawsuit, and International Patent Infringement Qui Tam Lawsuit Information

International theft of trade secret lawsuits,

International Pharmaceutical Supply Chains Include Active Pharmaceutical Ingredient (API) Manufacturers, Pharmaceutical Intermediate Manufacturers, and Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs by International Adulterated Drug Whistleblower Reward Lawyer Jason Coomer

International Pharmaceutical Supply Chains Include Active Pharmaceutical Ingredient (API) Manufacturers, Pharmaceutical Intermediate Manufacturers, and Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs by International Pharmaceutical Supply Chain Fraud Whistleblower Reward Lawyer, International Adulterated Drug Whistleblower Lawyer, and International Pharmaceutical Executive Whistleblower Reward Lawyer Jason S. Coomer

Pharmaceutical suppliers of raw materials to the pharmaceutical industry include suppliers of active pharmaceutical ingredients (APIs), intermediates, and excipients.   It is the United States Food and Drug Administration's expectation that current good manufacturing practices (CGMP) be used for the manufacturing, processing, packing, or holding (i.e., storage) of active pharmaceutical ingredients (APIs), intermediates, and excipients.  Further, the FDA recommends that laboratory controls should include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures to ensure that raw materials, intermediates, APIs, and containers conform to established standards of quality and purity.

Traditional West European and North American API Manufactures have been Replaced by Indian API Manufacturers and Chine API Manufacturers

The active pharmaceutical ingredient (API) market is very competitive with many producers with many API manufacturers specializing and targeting their manufacturing based on joint venture contracts, large pharmaceutical company demand, governmental procurement contracts, regional resources and availability of supplies, and other logistical and profit driven factors. Driven by profits and lower costs, API manufacturing has slowly been shifting from the historical leaders in Western countries to newer firms in India and China.  

The overall API market was valued at $101.08 billion in 2010, and is expected to grow at a CAGR of 7.9% from 2011 to 2016.  In 2005, the total world API market was $76B and growing at an average annual rate of 8.2%. The market share held by Indian API manufacturers in the global API merchant market (generic APIs and branded/innovator APIs) was 6.5% in 2005, 12.0% in 2010, and is expected to increase to 22.0% by 2015. India is expected to be the fastest growing API supplier during the next five years and will keep its position above China. 

The market share held by Chinese companies in the global API merchant market (generic APIs and branded/innovative APIs) has risen from 14.2% in 2005 to 19% in 2010. Although China remains the largest API supplier on a global basis, growth rates from 2005–2010 of Chinese API suppliers were less than those of Indian suppliers. China’s share of the Western European generic API merchant market fell from 39.2% in 2005 to 35% in 2010. China’s share of the US generic API merchant market increased slightly from 11.5% to 12.9% in 2010. While Italy still remains the world market leader in APIs destined to sectors such as cardiovascular or the central nervous system, China leads in anti-infective APIs.

As a generalization, Chinese firms have tended to focus on the earlier raw materials stage whereas Indian firms have tended to focus more on the final API manufacturing stage. In many cases, a Chinese firm will make the raw material for a pharmaceutical product and then sell it to an Indian firm who will then convert the raw material into an API. Then, either the same firm, another Indian firm, a global Multinational Corporation (MNC) or a final formulator in a developing country will convert the API into a final formulation product ready for the market. However, the situation is rapidly evolving as both China and India gain new manufacturing skills. Not surprisingly, while many Western API firms have been winding down and/or consolidating their manufacturing capacity, many firms in India and China have been increasing capacity to meet the growing demand.

Traditional West European and North American Excipient Manufacturers have been Replaced by Indian Excipient Manufacturers and Chine Exipient Manufacturers

Pharmaceutical excipients play an important role in pharmaceutical formulations by adding functionality or by facilitating the processing of a drug product.  Recent trends in the pharmaceutical excipient manufacturer industry include: geographic expansion and select investment in emerging markets.  The global market for excipients totaled $4.9 billion in 2011. That value is projected to reach more than $6.7 billion in 2016 after increasing at a five-year compound annual growth rate (CAGR) of 6.5%.   The global excipients market can be broken down by material type into three segments – organic, inorganic, and USP (U.S. pharmaceutical) water.   The segment made up of organic excipients held a value of nearly $4.6 billion in 2011, and is expected to grow at a CAGR of 6.6% to reach a value of nearly $6.3 billion in 2016. The segment made up of inorganic excipients, worth $268 million in 2011, should be worth $350 million in 2016, a CAGR of 5.5%. The USP water excipients segment totaled $92 million in 2011, and in 2016 that value should reach $114 million, a CAGR of 4.4%.

Increased globalization and strategies for securing the supply chain are important issues for excipient producers. The International Pharmaceutical Excipients Council (IPEC) expanded into China in July 2008 with the formation of IPEC–China.

Regulations for Pharmaceutical Ingredients and Raw Materials

Regulation for pharmaceutical ingredients and raw materials can be complicated and can change depending on where the pharmaceutical ingredients are coming from and where they are being sold.  As such, an international producer from China or India that manufactures an API or excipient that sells it to a final formulator in the United States can be subject to the regulatory authorities in China and the United States.  The API or excipient manufacturer should be required to produce the product to the quality standards enforced by the Chinese authorities as well as will be required to meet USFDA standards as well.

International Adulterated Drug Supply Chain Whistleblower Reward Lawyer, International Pharmaceutical Supply Chain Fraud Whistleblower Lawyer, Medical Device Supply Chain Illegal Kickback Lawyer, Medicine Supply Chain Whistleblower Reward Lawyer, Medicine Supply Chain Fraud Lawyer, and Pharmaceutical Supply Chain Foreign Corrupt Practices Act Lawyer

International Whistleblowers along the pharmaceutical supply chain and other health care professionals are being offered large potential rewards to blow the whistle on adulterated pharmaceutical ingredients, adulterated medicine, adulterated drugs, contaminated medical supplies, and defective medical devices.  These whistleblower rewards can come from SEC Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.  For more information on these potential whistleblower rewards, please feel free to go to the following web pages: Adulterated Drug Quality Assurance Supply Chain Whistleblower Reward Lawsuits, International Pharmaceutical Supply Chain Fraud Whistleblower Lawsuits, and Medicine Supply Chain Whistleblower Reward Lawsuits.

IRS Tax Fraud Confidential Whistleblower Reward Information by IRS Tax Fraud Illegal Offshore Account Whistleblower Lawyer Jason S. Coomer

IRS Illegal Offshore Account Tax Fraud Whistleblower Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Whistleblower Lawsuit, & other IRS Whistleblower Reward Lawsuit Information by IRS Illegal Offshore Account Tax Fraud Lawyer and Transfer Payment Tax Fraud Whistleblower Reward Lawyer Jason S. Coomer

Illegal Offshore Account Tax Fraud and Transfer Payment Tax Fraud are two forms of corporate tax fraud that are committed by large multinational corporations. The IRS is offering rewards and protections for IRS whistleblowers and IRS informants that work through Illegal Offshore Account Tax Fraud Whistleblower Lawyers, Multinational Corporate Tax Fraud Whistleblower Lawyers, and Transfer Payment Tax Fraud Whistleblower Lawyers to identify tax fraud schemes that cost the United States Billions of dollars.

IRS Illegal Offshore Account Tax Fraud Lawyer, Corporate Tax Fraud Whistleblower Reward Lawyer, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawyer, IRS Transfer Price Scheme Tax Fraud Lawyer, and IRS Whistleblower Reward Lawyer

Transfer pricing schemes involve the overpricing of imports and/or the underpricing of exports between related companies in different countries for the purpose of transferring profits or revenue out of the United States in order to evade taxes. The profits and revenue end up in a country that has a lower corporate tax rate than the US.  These fraudulent pricing schemes can be used both for stock manipulation and corporate tax fraud.  For more information on Corporate Tax Fraud Whistleblower Actions, please go to the following: Tax Fraud Whistleblower Reward Lawsuit, IRS Tax Fraud Whistleblower Award Lawsuit, and Corporate Tax Fraud Lawsuit Information web page.

Illegal Offshore Account Tax Fraud Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Lawsuit, IRS Whistleblower Reward Lawsuit, & IRS Whistleblower Payment for Detection of Fraud Lawsuit Information

In 2006, the Tax Relief and Health Care Act that was signed into law included a whistleblower reward amendment that created mandatory reward language to the IRS to create a mandatory economic incentive to encourage tax fraud whistleblowers to step forward to help the government detect large scale fraudulent schemes.  By offering large potential rewards for reporting multimillion tax fraud schemes, the IRS has received hundreds of tax fraud tips from tax fraud informants regarding taxpayer fraud and massive violations of the tax code costing taxpayers Billions of dollars.  Many of the tips already received include fraud schemes of hundreds of millions and tens of millions of dollars.  It is estimated that this programs will result in hundreds of billions of dollars or even Trillions of dollars in tax fraud being detected. 

The economic incentives in the Tax Whistleblower Reward Programs are designed to encourage insider tax fraud informants and tax fraud whistleblowers with knowledge and evidence of large tax violations and tax fraud schemes to step forward and report the massive tax fraud.  The IRS is hoping that there will be several tax fraud whistleblowers and tax fraud informants that will help them detect and collect on an estimated $3 Trillion in illegal offshore accounts as well as several other tax-avoidance schemes that have been perpetrated by billionaires and millionaires as well as large corporations.

Stock Manipulation Scheme Lawsuit, Corporate Accounting Fraud Lawsuit, Fraudulent Accounting Lawsuit, False Accounting Statement Lawsuit, SEC Whistleblower Incentive Program Lawsuit, & SEC Bounty Action Lawsuit Information by Texas Corporate Accounting Fraud Lawyer, Stock Manipulation Lawyer, & False Accounting Statement Lawyer Jason Coomer

Stock manipulations schemes, false accounting statements, and other types of corporate accounting fraud cost pension funds and investors hundreds of Billions of dollars.  These fraudulent business practices are the target of new SEC Bounty Action laws and rules that encourage whistleblowers to anonymously step up and blow the whistle through a Bounty Action Lawyer on illegal stock manipulation schemes, false accounting, accounting fraud, Ponzi schemes, and other SEC violations.  By working with a stock manipulation bounty action lawyer to expose stock manipulation schemes, false misleading information on a company's financial statements, false information on Securities and Exchange Commission (SEC) filings, insider trading; embezzlement by stockbrokers; and other securities fraud, a SEC whistleblower can receive a large financial reward.  

 

Illegal Offshore Account Tax Fraud Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Lawsuit, & IRS Whistleblower Reward Lawsuit Information by Illegal Offshore Account Tax Fraud Lawyer and Transfer Payment Tax Fraud Whistleblower Reward Lawyer Jason S. Coomer

The Federal Government including the SEC and IRS have recently amended and strengthened whistleblower reward laws to encourage accountant whistleblowers, financial analyst whistleblowers, and other high end professional whistleblowers with evidence of Accounting Fraud, Tax Fraud, Stock Manipulation Fraud, and other Investment Fraud to step up and blow the whistle on these fraud schemes.  By working through a Accounting Fraud Whistleblower Lawyer, Tax Fraud Whistleblower Lawyer, Stock Manipulation Fraud Whistleblower Lawyer, or other SEC Investment Fraud Whistleblower Lawyer, these whistleblowers can protect their identity and obtain large economic rewards.

For more information on these Whistleblower Reward, Bounty Action, and Protection Laws, feel free to go to the following web pages: Corporate Tax Fraud Lawsuits & Tax Fraud Whistleblower Lawsuit Information, Employee Whistleblower Award & Recovery Lawsuit Information, Corporate Illegal Kickback & Contract Bribe Whistelblower Award Lawsuit Information, Foreign Corrupt Practices Act Lawyer and SEC Bounty Action Lawsuit Information,  Confidential Financial Analyst Whistleblower Reward Lawsuit Information, Stock Manipulation Scheme & Corporate Accounting Fraud Lawsuit Information, and Multinational Corporation Tax Fraud Web Page Illegal Offshore Account Whistleblower and Multinational Corporation Fraudulent Transfer Payment Bounty Lawsuit Information

Fueled by Economic Incentives Many States Are Enacting Strong Medicaid Fraud Whistleblower Reward Laws That Provide Rewards and Protection to Whistleblowers by Medicaid Fraud Whistleblower Lawyer Jason S. Coomer

New State Medicaid Whistleblower Reward Laws Allow Medicaid Fraud Whistleblower Lawyers, Medicaid Hospital Employee Whistleblower Reward Lawyers, Hospital Whistleblower Lawyers, and Hospital Medicaid Fraud Whistleblower Lawyers to Protect Hospital Employee Whistleblowers From Retaliation

New state whistleblower reward laws are expanding the ability of Medicaid fraud whistleblowers to collect large economic rewards to encourage health care providers to blow the whistle on health care fraud including illegal Medicaid retention of overpayments, Medicaid illegal kickback schemes, Medicaid upcoding practices, Medicaid double billing practices, Medicaid false coding practices, Medicaid unbundling, and other fraudulent Medicaid billing practices.

The 2009 Fraud Enforcement and Recovery Act (FERA) and many new state Medicaid fraud whistleblower laws are expanding Medicaid fraud whistleblower recovery laws and other Bounty Reward Actions to increase potential rewards for relators, expand potential liability for Medicaid fraud criminals and violators, and to increase protections to Medicaid fraud whistleblowers. These new laws are designed to help the Federal government and state governments identify, recoup, and crack down on Medicaid fraud, Medicare fraud, and other forms of health care fraud which is estimated to be over $100 Billion per year.

With Medicare and Medicaid costs continuing to grow and many government budgets being tight, it is essential that health care providers with knowledge of Medicaid fraud, Medicare fraud, or other health care fraud to step up and expose the health care fraud and systematic Medicaid fraud that is the fasting growing and most lucrative crimes in the United States.

In developing and strengthening Medicaid fraud whistleblower laws, governments are setting up increased whistleblower protections and economic incentives to encourage health care providers to blow the whistle on traditional qui tam health care fraud causes of action and are expanding the causes of action to include rewards to whistleblowers that expose retention of Medicaid overpayments. Many of these False Claims Act statutes and Medicaid Fraud statutes have also been expanded to include government contractor false claims, government grantee false claims, and other recipients of government money that submit false claims to obtain this money.

For more information on potential Medicaid fraud whistleblower recoveries and Medicaid fraud whistleblower protections, please feel free to go to the following web pages:  Medicaid Fraud Whistleblower Lawsuit and Medicaid Fraud Whistleblower Reward Lawsuit Information and Medicaid Fraud Whistleblower Lawyer and Medicaid Whistleblower Reward Lawyer.

If your health care company has people that are committing Medicaid fraud, it is important to contact a Medicaid fraud whistleblower reward lawyer, Medicaid illegal kickback whistleblower reward lawyer, Medicaid upcoding whistleblower reward lawyer, Medicaid protected whistleblower double billing lawyer, Medicaid false coding whistleblower reward lawyer, Medicaid unbundling fraud whistleblower lawyer, or other health care fraud whistleblower lawyer to maximize your ability to obtain a substantial whistleblower recovery, understand whistleblower protections from potential retaliation, and protect yourself from potential liability.

Off Label Drug Marketing Fraud Lawsuit and Drug Formulary Fraud Lawsut Information

Drug Formulary Fraud Whistleblower Lawsuit Information, Drug Company Off Label Marketing Fraud Whistleblower Lawsuit Information, Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lasuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information (Off Label Marketing Fraud, Hospital Formulary Fraud, & Drug Kickback Whistleblower Lawyer) 

Many health care professions have become aware of the strong influence that drug companies now have in determining community standards of care for medication use in patients.  These drug companies push drug samples into many hospitals and often use powerful forms of manipulation including biased research, influencing key medical doctors, and kickbacks to get their drugs placed on hospital formularies. 

Because of the immense power and influence of drug companies, it is becoming common to have drug marketing executives and representative to be able to influence what drugs whole communities.  In many situations the drug companies are more powerful than individual doctors that are forced to follow hospital formularies.  This drug company manipulation of the medical community can be extremely dangerous because it takes important medical decisions out of the hands of individual medical doctors and allows the drug companies to push potentially dangerous drugs for off-label drug uses and in inappropriate situations. 

The drug industry's main goal is to make a profit.  Each drug company is trying to sell as much of their drug as they can regardless of the potential danger to patients or if there are cheaper more effective alternatives available.  If the marketing executives and drug representatives can get their drug placed on a hospital formulary or make it the standard of care in a community, they are able to make lots of money.  Once this is accomplished there are economic incentives to keep expanding the use of the drug to keep expanding off-label uses. 

Recently several large drug companies have been caught fraudulently marketing drugs for off-label purposes.  These drug companies have had to pay Billions of dollars for Medicare Marketing Fraud Off-Label Lawsuits, Medicaid Marketing Fraud Off-Label Lawsuits, and other health care fraud lawsuits.   Despite these large fines, Drug Companies have continued this practice because they are making profits of Hundreds of Billions of Dollars.

"WASHINGTON (AP) -- Federal prosecutors hit Pfizer Inc. with a record-breaking $2.3 billion in fines Wednesday and called the world's largest drug maker a repeating corporate cheat for illegal drug promotions that plied doctors with free golf, massages, and resort junkets." Pfizer to pay record $2.3B penalty over promotions Repeat offender Pfizer paying record $2.3B settlement for illegal drug promotions By Devlin Barrett, Associated Press Writer On Wednesday September 2, 2009, 3:47 pm EDT

The Department of Justice has announced that this penalty is a warning to all drug manufacturers that criminal and civil prosecution of fraudulent drug marketing, fraudulent off label marketing, illegal kickbacks, and other fraud schemes.  They have also announced that there are several new Medicare Fraud and Medicaid Fraud Law Enforcement Teams that are cracking down on Medicare Fraud and Medicaid Fraud Schemes.  These teams will be investigating and prosecuting people that have profited from these scheme and people that knew about the fraudulent scheme, but failed to report them.

Drug Formulary Fraud Whistleblower Lawsuit Information, Drug Company Off Label Marketing Fraud Whistleblower Lawsuit Information, Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lasuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information (Off Label Marketing Fraud, Hospital Formulary Fraud, & Drug Kickback Whistleblower Lawyer) 

 Medical doctor whistleblowers, physician whistleblowers, neurologist whistleblowers, health care administrator whistleblowers, pharmacist whistleblowers, nurse whistleblowers, or other medical professional  whistleblowers are needed to blow the whistle on Billions of dollars in Off Label Drug  Fraud. and Hospital Formulary Drug Fraud.  If you are aware of hospital formulary drug fraud, fraudulent off label marketing practices, or illegal drug kickbacks, it is extremely important that you step forward and blow the whistleblower on the fraud.  It not only helps prevent the billions of dollars that are stolen each year from Medicare, Medicaid, and taxpayers, but can lead to a large whistleblower reward for properly reporting the fraud and can help prevent potential criminal liability for failing to report drug marketing fraud.

For more information on a Drug Formulary Fraud Whistleblower Lawsuit or Drug Company Off Label Marketing Fraud Whistleblower Lawsuit, please go to the following webpage on Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lawsuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information.

Securties Fraud Whistleblower Lawsuit Information and Investment Fraud Whistleblower Bounty Actions

Financial Fraud Whistleblower Lawsuits, Securities Fraud Whistleblower Bounty Actions, SEC Whistleblower Incentive Program Claims, Securties Fraud Whistleblower Lawsuit Information, & Dodd-Frank Act Financial Fraud Whistleblower Bounty Actions Provide Economic Incentives for Wall Street Fraud and Financial Fraud Whistleblowers by Texas Securities, Commodity, and Financial Fraud Whistleblower Lawyer Jason Coomer

In the aftermath of unregulated investments that brought the US economy to the brink of collapse and cost investors Trillions of dollars, the federal government is offering financial incentives to securities fraud whistleblowers, commodity fraud whistleblowers, stimulus fraud whistleblowers, and other financial fraud whistleblowers to step up and blow the whistle on investment fraud, Securities and Exchange Commission SEC violations, Commodity Future Trading Commission CFTC violations, derivative fraud, securities fraud and other forms of financial fraud.  Recent legislation not only strengthens existing qui tam and whistleblower protection laws, but also creates new whistleblower bounties that can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud. 

These new whistleblower bounty actions are expected to encourage Wall Street whistleblowers and other investment fraud whistleblowers to come forward and blow the whistle on large scale investment fraud.  By  encouraging investment fraud whistleblowers to expose investment fraud scams and SEC violations committed by the financial industry, Congress is hoping to rebuild confidence in Wall Street and the Financial Sector for investors.

  

Dodd-Frank Wall Street Reform and Consumer Protection Act Created the SEC Incentive Program Allowing New Whistleblower Bounty Provisions that allows Qualified Financial Fraud Whistleblowers, Securities Fraud Whistleblowers, and SEC Violation Whistleblowers to Collect Rewards for SEC Bounty Claims

In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act was signed into law which includes significant new financial fraud bounty whistleblower provisions.  These provisions create economic incentives for SEC violation whistleblowers and other financial fraud whistleblowers with "original information" of SEC violations and financial fraud to blow the on large scale financial fraud and SEC violations.  

These SEC bounty claims must be brought voluntarily under the SEC Bounty Programs by one or more individuals.  The whistleblower or whistleblowers must be a natural person or natural persons, companies or other entity is not eligible to be financial fraud bounty whistleblowers.  Successful SEC violation bounty whistleblowers and financial fraud whistleblowers can collect financial rewards for whistleblower bounty actions that result in the imposition of monetary sanctions of greater than $1 million dollars.  This new financial fraud SEC bounty program is called the "Securities Whistleblower Incentives and Protection". 

Through SEC Whistleblower Bounty Actions the SEC will award between ten percent and thirty percent of the money collected to a qualified whistleblower who voluntarily provides the SEC with original information about a violation of the securities laws that leads to a successful enforcement of an action brought by the SEC that results in monetary sanctions exceeding $1,000,000.00.  

So long as the financial fraud whistleblower or financial fraud whistleblowers base their claims on "original information", any person (not just an employee or insider) may file a SEC financial fraud bounty claim.  Further, if the financial fraud whistleblower is represented by an attorney, the whistleblower may file the financial fraud bounty claim anonymously.  However, before the financial fraud bounty award is paid, the whistleblower's identity shall be revealed to the SEC and SEC shall be provided information about the whistleblower that it requests. 

Securities Fraud Whistleblower Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Financial Fraud Derivatives Lawsuit Information, Financial Fraud Whistleblower Lawsuit Information, & Financial Fraud Bounty Lawsuit Information

Securities fraud, also known as stock fraud and investment fraud, is the unlawful practice of inducing investors to make investment decisions on the basis of false information, frequently resulting in losses, in violation of the securities laws.  Securities fraud whistleblower lawsuits include deceptive practices in the stock and commodity markets, and occur when investors are enticed to part with their money based on fraudulent misrepresentations.  

Securities fraud whistleblower lawsuits include outright theft from investors and misstatements on a public company's financial reports as well as a wide range of other actions, including insider trading, front running and other illegal acts on the trading floor of a stock or commodity exchange.  Evidence for a securities fraud whistleblower lawsuit may include:

1. False or misleading information on a company's financial statement;
2. False or misleading information on Securities and Exchange Commission (SEC) filings;
3. Lying to corporate auditors;
4. Insider trading;
5. Stock manipulation schemes;
6. Embezzlement by stockbrokers;
7. Manipulation of a security’s price or volume;
8. Fraudulent or unregistered offer or sale of securities, including Ponzi schemes, high yield investment programs or other investment programs;
9. Brokerage Account and Retirement Account Fraud;
10. False or misleading statements about a company;
11. Failure to file required reports with the SEC;
12. Abusive naked short selling;
13. Theft or misappropriation of funds or securities;
14. Fraudulent conduct or other problems associated with municipal securities transactions or public pension plans; and
15. Bribery of foreign officials

Through new legislation the federal government is offering financial incentives to securities fraud whistleblowers and other financial fraud whistleblowers to step up and blow the whistle on properly reporting financial fraud including the above listed forms of securities fraud that lead to SEC violations and fines.  These new whistleblower bounties can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud.

Other forms of SEC Violations including reporting problems with a brokerage or advisory account; fraudulently preventing access to funds or securities; fraudulent order handling, trade execution, or confirmations; fraudulent fees, mark-ups or commissions; and inaccurate or misleading disclosures by financial professionals, may also lead to potential SEC bounties, if the fraudulent acts result in fines of over $1 million and are properly reported.

Securities Fraud Whistleblower Lawsuit Information, SEC Violation Whistleblower Bounty Lawsuit Information, Dodd-Frank Act Financial Fraud Whistleblower Bounty Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Investment Fraud Whistleblower Lawsuit Information, Securities Fraud Action Information, Commodity Fraud Action Information, and SEC Fraud Whistleblower Lawsuit Information

Financial Fraud Whistleblower Lawsuits, Securities Fraud Whistleblower Lawsuits, Commodity Fraud Whistleblower Lawsuits, Stimulus Fraud Whistleblower Lawsuits, and SEC Violation Whistleblower Lawsuits will become more common with the enactment of laws like the Dodd-Frank Wall Street Reform and Consumer Protection Act that create bounties that can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud that result in monetary sanctions over one million dollars ($1,000,000.00).  The SEC can award the whistleblower up to 30% of the money collected.

By creating whistleblower bounties for investors and people with specific information of financial fraud, it is expected that hard to detect financial fraud including derivative market fraud and investment fraud will be exposed to help regulate the financial market and prevent large investment corporations, banks, hedge funds, and other large corporations from committing financial fraud of billions of dollars.

TARP Fraud Whistleblower Lawsuits, Bail Out Fraud Whistleblower Lawsuits, Financial Fraud Federal False Claims Act Lawsuits, and Stimulus Fraud Qui Tam Whistleblower Lawsuits

Many financial fraud whistleblower lawsuits may include also include elements of stimulus fraud whistleblower qui tam lawsuits or other Federal False Claims Act Lawsuits.  These potential Financial Fraud Actions under the Federal False Claims Act may allow a stimulus fraud whistleblower or other financial fraud whistleblower to potentially collect a large recovery for blowing the whistle on financial fraud. The Troubled Asset Relief Program (TARP) is a $700 Billion Bail Out of the troubled United States Banking and Credit System.  It was designed to unfreeze the credit market and enable the government to purchase residential and commercial mortgage assets, including whole loans and securities.  Unfortunately, after it was announced numerous Corporate interests began scheming on how to get as much of the Bail Out money as possible and use the money not for its intended purpose, but to enrich the corporations, shareholders, and CEOs that were able to get a portion of the money.

When a government imposes a penalty, for the doing or not doing an act, and gives that penalty in part to whistleblowers that will sue for the same, and the other part of the recovery goes to the government, and makes it recoverable by action, such actions are called "qui tam actions", the plaintiff is suing on their own behalf as well for the government and taxpayers. Qui tam provisions of the False Claims Act are based on the theory that one of the least expensive and most effective means of preventing frauds on taxpayers and the government is to make the perpetrators of government fraud liable to actions by private persons acting under the strong stimulus of personal ill will or the hope of gain.

The strong public policy behind creating an economic gain for whistleblowers is that  the government would be significantly less likely to learn of the allegations of fraud, but for persons in certain positions with specialized knowledge of fraud that has been committed. Congress has made it clear that creating this economic incentive is beneficial not only for the government, taxpayers, and the realtor, but is an efficient method of regulating government to prevent fraud and fraudulent schemes.

The central purpose of the qui tam provisions of the False Claims Act is to set up incentives to supplement government regulation and enforcement by encouraging whistleblowers with specialized knowledge of fraud going on in the government to blow the whistle on the crime.

The whistleblower's share of recovery is a maximum of 30 percent and the government's prior knowledge of fraud now does not necessarily bar a whistleblower from collecting lost revenue. If the government takes over the lawsuit, the relator can "continue as a party to the action." The defendant is also required to pay for the relator's attorney fees. The whistleblower is also protected from retaliatory actions by his or her employer. As a result a 1986 amendment to the False Claims Act, qui tam lawsuits have increased dramatically.   Though the amendment was first made for corrupt defense contractors, the amendment has uncovered billions of dollars in health care fraud and will probably apply to fraudulently obtained TARP and Bail Out Funds. 

Securities Fraud Whistleblower Lawsuit Information, SEC Violation Whistleblower Bounty Lawsuit Information, Dodd-Frank Act Financial Fraud Whistleblower Bounty Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Investment Fraud Whistleblower Lawsuit Information, Securities Fraud Action Information, Commodity Fraud Action Information, and SEC Fraud Whistleblower Lawsuit Information

Through Federal False Claims Act Whistleblower Lawsuits, Qui Tam Lawsuits, and other Government Fraud Lawsuits, billions of dollars have been recovered from fraudulent government contractors and corporations that have committed fraud and stolen large amounts of money from the government and taxpayers.  By seeking the knowledge of sophisticated investors, the SEC is seeking to use their specialized knowledge of securities and investments to expose complicated securities fraud and investment fraud that threaten the public confidence in Wall Street, the financial industry, and investing.

For more information on Investment Fraud Whistleblower Lawsuits including Securities Fraud, Derivatives Fraud, Investment Fraud, and Commodity Fraud follow the following link:  Securities Fraud Whistleblower Bounty Actions and Financial Fraud Whistleblower Lawsuits.

Drug Calibration Fraud Whistleblower Lawsuit Information and Drug Safety Fraud Whistleblower Lawsuit Information

Drug Calibration Fraud Whistleblower Lawsuit Information, Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Drug Quality Assurance Whistleblower Lawsuit Information  by Drug Safety Fraud Whistleblower, Contaminated Drug Whistleblower, Adulterated Drug Whistleblower, Drug Calibration Fraud Whistleblower, and Pharmaceutical Quality Assurance Whistleblower Lawyer Jason S. Coomer

It is extremely important that pharmaceutical whistleblowers including Drug Quality Fraud Assurance Whistleblowers, Drug Calibration Fraud Whistleblowers, and other Drug Safety Whistleblowers continue to step forward to blow the whistle on adulterated drugs that threaten the health and safety of the people taking medications.  Because of the serious potential danger to the public that can be caused by giving contaminated drugs or improperly calibrated drugs, it is vitally important that whistleblowers help make sure that drugs are properly calibrated and not contaminated.  Further, it is clear that the government will not tolerate any lapses in safety standards from pharmaceutical manufacturers. 

Public policy dictates that whistleblowers and the government work together through large economic incentives and law enforcement to regulate the $800 Billion a year Pharmaceutical Industry to make sure that drug calibration fraud and drug safety fraud are not occurring.  By encouraging pharmaceutical quality assurance, calibration, and safety professionals to step forward and expose fraudulent practices that create adulterated drugs, large awards through the False Claims Act protect the health and lives of children, men, and women.  These awards encourage insiders with special knowledge of drug calibration fraud and drug safety fraud to come forward and blow the whistle on large companies that value profits over drug safety.  

There are several keys to a successful False Claims Act Qui Tam Whistleblower action including 1) obtaining original and specialized information of the fraud, 2) being the first to file regarding the specific fraud, and 3) protecting the whistleblower for retaliation.  Pharmaceutical whistleblowers including Drug Quality Assurance Whistleblowers, Drug Calibration Whistleblowers, and other Drug Safety Whistleblowers that timely and properly blow the whistle on defective and dangerous drugs, may receive a large amount of money for being the first to properly report fraudulent disregard for safety standards and pharmaceutical policies that hide adulterated drugs.   

Pharmaceutical Quality Assurance Whistleblower Lawsuit Information, Drug Safety Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Pharmaceutical Drug Calibration Whistleblower Qui Tam Lawsuit Information by Drug Quality Whistleblower, Contaminated Drug Whistleblower, Adulterated Drug Whistleblower, and Pharmaceutical Quality Assurance Whistleblower Lawyer

 

Health Care Fraud costs United States Tax Payers approximately $90 billion each year through Medicare, Medicaid, and other government health care programs.  This has prompted increased law enforcement of fraud against the FDA, Medicare, and Medicaid.  This increased enforcement by FDA and the offer of large economic incentives to drug calibration fraud whistleblowers and safety fraud whistleblowers is expected expose a large amount of pharmaceutical drug calibration fraud and safety fraud.  

 

It is important for pharmaceutical safety and drug calibration fraud whistleblowers to not delay in coming forward with a False Claim Act Qui Tam Action for many reasons.  First, by coming forward it can expose drug calibration fraud and drug safety fraud that endangers the lives on men, women, and children.  Second, only the first drug calibration fraud whistleblower to file is eligible to be a relator and may make a large recovery for exposing the drug calibration fraud or drug safety fraud.  Third, when the fraudulent  drug calibration scheme is exposed, the people that kept the fraud secret can sometimes be found liable for criminal activity for not exposing the drug safety fraud that was being committed and be held liable for continuing criminal activity.

Drug Calibration Fraud Whistleblower Lawsuit Information, Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Drug Quality Assurance Whistleblower Lawsuit Information

Drug Calibration Fraud Whistleblower Lawsuits, Drug Safety Fraud Whistleblower Lawsuits, and Contaminated Drug Whistleblower Lawsuits are becoming more common as Pharmaceutical Quality Assurance Managers, Drug Calibration Specialists, and other Drug Safety Whistleblowers are stepping forward to blow the whistle on adulterated drugs, contaminated drugs, and poorly calibrated drugs that threaten the health and lives of children, women, and men that are taking the drugs. 

For more information on Drug Safety Fraud Lawsuits, please go to the following web page on Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Pharmaceutical Drug Calibration Fraud Whistleblower Lawsuit Information.